Dianthus Therapeutics, Inc. (DNTH) shareholders
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$92.48+3.18 (+3.56%)
Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
66M of 56M shares
Institutional holders
269
63 new, 32 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 75 sales
Net sold $82.43M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 5,970,638 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (14.00%) | 4,482,609 | 14.00% | 13G (passive) amendment | Mar 31, 2025 |
| Peter Evan Harwin Joint filing with Fairmount Funds Management LLC (9.90%), Fairmount Healthcare Fund II L.P. (9.90%) and 1 more | 4,052,052 | 9.90% | 13D (active) amendment | Sep 11, 2025 |
| T. Rowe Price Investment Management, Inc. | 3,888,456 | 7.10% | 13G (passive) | Jun 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.50%), Rajeev Shah (9.50%) and 1 more | 3,866,733 | 9.50% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 3,504,166 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (5.90%), Wellington Investment Advisors Holdings LLP (5.90%) and 1 more | 3,229,882 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (6.90%), Steven A. Cohen (6.90%) | 2,981,674 | 6.90% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Capital Management | 2,846,786 | 5.08% | 13G (passive) | Sep 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (6.00%), Peter Kolchinsky (6.00%) and 1 more | 2,611,733 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (6.50%), Wellington Investment Advisors Holdings LLP (6.50%) and 1 more | 2,577,662 | 6.50% | 13G (passive) | Sep 30, 2025 |
| Octagon Capital Advisors LP Joint filing with Ting Jia (6.10%), Octagon Investments Master Fund LP (5.30%) | 2,416,667 | 6.10% | 13G (passive) amendment | Sep 30, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (7.34%), Deep Track Biotechnology Master Fund, Ltd. (7.34%) | 2,357,702 | 7.34% | 13G (passive) | Mar 17, 2025 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.30%) | 1,700,069 | 5.30% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DNTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,199,893 | 14.66% | $799.33M | +432,207 | 0.03% |
| BlackRock, Inc. | 4,123,822 | 7.37% | $401.99M | +948,119 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 3,888,456 | 6.95% | $379.05M | +2,596,274 | 0.25% |
| Wellington Management Group Llp | 3,229,882 | 5.77% | $314.85M | +634,099 | 0.05% |
| Fairmount Funds Management LLC | 2,537,191 | 4.54% | $247.33M | – | 16.35% |
| Price T Rowe Associates Inc /Md/ | 2,514,946 | 4.50% | $245.16M | +1,367,998 | 0.02% |
| State Street Corp | 2,357,440 | 4.21% | $229.80M | +958,527 | 0.01% |
| Vanguard Capital Management LLC | 2,159,568 | 3.86% | $210.51M | +128,319 | 0.00% |
| Avidity Partners Management LP | 2,104,184 | 3.76% | $205.12M | −2,104,184 | 32.85% |
| Octagon Capital Advisors LP | 1,841,667 | 3.29% | $179.53M | −105,000 | 16.14% |
| TCG Crossover Management, LLC | 1,676,624 | 3.00% | $163.44M | – | 3.93% |
| Fred Alger Management, LLC | 1,302,493 | 2.33% | $126.97M | +140,570 | 0.42% |
| Geode Capital Management, LLC | 1,258,502 | 2.25% | $122.70M | +342,291 | 0.01% |
| VR Adviser, LLC | 1,180,000 | 2.11% | $115.03M | – | 3.49% |
| UBS Group AG | 1,140,260 | 2.04% | $111.15M | +358,978 | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 1,125,313 | 2.01% | $109.70M | +105,500 | 1.14% |
| Jennison Associates LLC | 1,021,763 | 1.83% | $99.60M | +536,627 | 0.06% |
| Polar Capital Holdings Plc | 1,018,726 | 1.82% | $99.31M | −57,283 | 0.23% |
| Citadel Advisors LLC | 974,911 | 1.74% | $95.03M | −635,572 | 0.01% |
| Franklin Resources Inc | 968,983 | 1.73% | $94.46M | +801 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 269 | 66M | 100.0% | 63 / 117 | 69 / 32 | 14M | 12M |
| Q1 2026 | 241 | 64M | 100.0% | 97 / 84 | 54 / 20 | 24M | 7M |
| Q4 2025 | 166 | 49M | 87.8% | 47 / 76 | 26 / 18 | 11M | 9M |
| Q3 2025 | 140 | 47M | 83.8% | 51 / 43 | 34 / 13 | 16M | 8M |
| Q2 2025 | 102 | 39M | 69.9% | 18 / 30 | 39 / 14 | 5M | 3M |
| Q1 2025 | 98 | 38M | 67.4% | 16 / 29 | 31 / 12 | 7M | 4M |
| Q4 2024 | 95 | 35M | 62.8% | 16 / 40 | 25 / 12 | 6M | 2M |
| Q3 2024 | 91 | 31M | 56.1% | 25 / 31 | 20 / 6 | 5M | 2M |
| Q2 2024 | 74 | 30M | 53.1% | 28 / 18 | 17 / 30 | 6M | 2M |
| Q1 2024 | 76 | 26M | 46.7% | 39 / 24 | 8 / 2 | 17M | 1M |
| Q4 2023 | 39 | 11M | 19.0% | 10 / 12 | 6 / 1 | 1M | 0M |
| Q3 2023 | 30 | 10M | 18.0% | 30 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
305 funds held DNTH in Q2 2026, 26% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DNTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,649,920 | 2.95% | $160.83M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,594,117 | 2.85% | $148.27M | 0.15% | May 31, 2026 |
| Vanguard Health Care Fund | 1,503,955 | 2.69% | $160.80M | 0.42% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,302,913 | 2.33% | $127.01M | 1.18% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,214,601 | 2.17% | $118.40M | 0.14% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1,155,511 | 2.07% | $112.64M | 1.21% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 730,062 | 1.31% | $78.06M | 3.55% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 673,057 | 1.20% | $65.61M | 0.45% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 624,586 | 1.12% | $60.88M | 1.21% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 517,343 | 0.92% | $55.31M | 0.16% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 514,500 | 0.92% | $50.15M | 0.22% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 468,387 | 0.84% | $50.08M | 0.57% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 457,638 | 0.82% | $44.61M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 453,246 | 0.81% | $44.18M | 0.45% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 444,440 | 0.79% | $43.32M | 0.28% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marino Garcia | CEO AND PRESIDENT, Director | 65,292 | 0.12% | Aug 7, 2026 |
| Ryan Savitz | EVP, CFO & CBO | 0 | – | Nov 12, 2026 |
| Edward Carr | CHIEF ACCOUNTING OFFICER | 700 | 0.00% | Sep 18, 2026 |
| Simrat Randhawa | EVP, Head of R&D | 4,000 | 0.01% | Sep 3, 2026 |
| Adam M. Veness | SVP, General Counsel and Sec. | 15,000 | 0.03% | Aug 14, 2026 |
| Simon Read | Director | 0 | – | Aug 19, 2026 |
| Anne McGeorge | Director | 1,250 | 0.00% | Aug 11, 2026 |
| Steven J. Romano | Director | – | – | May 22, 2026 |
| Jonathan Violin | Director | – | – | May 22, 2026 |
| Alison Frances Lawton | Director | – | – | May 22, 2026 |
| Paula Soteropoulos | Director | 0 | – | May 22, 2026 |
| Sujay Kango | Director | – | – | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ryan Savitz EVP, CFO & CBO | Nov 12, 2026 | Sale(10b5-1 plan) | −17,724 | $90.56 | $1.61M | 0 |
| Ryan Savitz EVP, CFO & CBO | Nov 12, 2026 | Option exercise | +16,385 | $22.07 | $361.62K | 17,724 |
| Ryan Savitz EVP, CFO & CBO | Nov 12, 2026 | Option exercise | +1,339 | $21.77 | $29.15K | 1,339 |
| Ryan Savitz EVP, CFO & CBO | Nov 11, 2026 | Sale(10b5-1 plan) | −3,044 | $90.03 | $274.05K | 0 |
| Ryan Savitz EVP, CFO & CBO | Nov 11, 2026 | Option exercise | +1,300 | $22.07 | $28.69K | 3,044 |
| Ryan Savitz EVP, CFO & CBO | Nov 11, 2026 | Option exercise | +1,744 | $21.77 | $37.97K | 1,744 |
| Ryan Savitz EVP, CFO & CBO | Nov 10, 2026 | Sale(10b5-1 plan) | −2,561 | $90.14 | $230.85K | 0 |
| Ryan Savitz EVP, CFO & CBO | Nov 10, 2026 | Option exercise | +1,260 | $22.07 | $27.81K | 2,561 |
| Ryan Savitz EVP, CFO & CBO | Nov 10, 2026 | Option exercise | +1,301 | $21.77 | $28.32K | 1,301 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −2,064 | $91.59 | $189.04K | 0 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −58,396 | $90.90 | $5.31M | 2,064 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −37,517 | $90.12 | $3.38M | 60,460 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −1,736 | $88.84 | $154.23K | 97,977 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −700 | $86.70 | $60.69K | 99,713 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Sale(10b5-1 plan) | −300 | $85.16 | $25.55K | 100,413 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Option exercise | +10,399 | $8.44 | $87.77K | 100,713 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Option exercise | +40,430 | $22.07 | $892.29K | 90,314 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Option exercise | +20,608 | $21.77 | $448.64K | 49,884 |
| Ryan Savitz EVP, CFO & CBO | Nov 9, 2026 | Option exercise | +29,276 | $17.88 | $523.45K | 29,276 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −1,100 | $103.20 | $113.52K | 700 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −700 | $104.39 | $73.07K | 0 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −3,501 | $102.39 | $358.47K | 1,800 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −6,771 | $101.37 | $686.38K | 5,301 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −7,928 | $100.43 | $796.21K | 12,072 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Option exercise | +20,000 | $17.88 | $357.60K | 20,000 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −13,309 | $106.74 | $1.42M | 4,000 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −7,215 | $106.25 | $766.59K | 17,309 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −2,600 | $105.19 | $273.49K | 24,524 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +9,375 | $22.07 | $206.91K | 27,124 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +6,249 | $21.77 | $136.04K | 17,749 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +7,500 | $17.88 | $134.10K | 11,500 |
| Simon Read Director | Aug 19, 2026 | Sale(10b5-1 plan) | −2,778 | $117.55 | $326.55K | 0 |
| Simon Read Director | Aug 19, 2026 | Option exercise | +2,778 | $18.36 | $51.00K | 2,778 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 13, 2026 | Option exercise | +15,000 | $18.17 | $272.55K | 15,000 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −470 | $111.05 | $52.19K | 397 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −397 | $111.77 | $44.37K | 0 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −272 | $109.96 | $29.91K | 867 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −831 | $108.95 | $90.54K | 1,139 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −737 | $108.17 | $79.72K | 1,970 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −70 | $107.11 | $7.50K | 2,707 |
| Simon Read Director | Aug 10, 2026 | Option exercise | +2,777 | $18.36 | $50.99K | 2,777 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 10, 2026 | Sale(10b5-1 plan) | −16,167 | $110.38 | $1.78M | 0 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 10, 2026 | Option exercise | +16,167 | $17.88 | $289.07K | 16,167 |
| Anne McGeorge Director | Aug 10, 2026 | Option exercise | +1,250 | $19.36 | $24.20K | 1,250 |
| Anne McGeorge Director | Aug 10, 2026 | Option exercise | +6,500 | $11.20 | $72.80K | 7,750 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,450 | $107.58 | $155.99K | 6,300 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −2,800 | $108.38 | $303.46K | 3,500 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,800 | $109.30 | $196.74K | 1,700 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −700 | $111.41 | $77.99K | 0 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,000 | $110.64 | $110.64K | 700 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Option exercise | +3,833 | $17.88 | $68.53K | 3,833 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Sale(10b5-1 plan) | −3,217 | $110.61 | $355.83K | 616 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Sale(10b5-1 plan) | −616 | $111.18 | $68.49K | 0 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −21,909 | $108.72 | $2.38M | 65,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −10,384 | $107.49 | $1.12M | 220,908 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Option exercise | +126,000 | $8.44 | $1.06M | 231,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Option exercise | +40,000 | $8.44 | $337.60K | 105,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −23,907 | $108.05 | $2.58M | 197,001 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −104,091 | $107.96 | $11.24M | 87,102 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −800 | $110.76 | $88.61K | 191,292 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
18.25%
9M shares short
Days to cover
10.1
At 1M shares a day
Change since last report
+3.2%
From 9M shares
Short volume, 20 days
55.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dianthus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 82,070 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ryan Savitz Officer | Nov 9, 2026 | 124,042 | $10.67M | Nov 9, 2026 | Exercise of Stock Options |
| Edward Carr Officer | Sep 17, 2026 | 20,000 | $2.05M | Sep 17, 2026 | Exercise of Stock Options |
| Simrat Randhawa Officer | Sep 1, 2026 | 23,124 | $2.44M | Sep 1, 2026 | Exercise of Stock Options |
| Adam M. Veness Officer | Aug 10, 2026 | 16,167 | $1.76M | Aug 10, 2026 | Exercise of Stock Options |
| Simon Read Officer | Aug 10, 2026 | 5,550 | $624.38K | Aug 10, 2026 | Stock Option Exercise |
| Anne McGeorge Director | Aug 10, 2026 | 7,750 | $844.13K | Aug 10, 2026 | Exercise of Stock Options |
| Marino Garcia Officer | Aug 7, 2026 | 126,000 | $13.62M | Aug 7, 2026 | Exercise of Options Under a Registered Plan |
| Adam M. Veness Officer | Aug 7, 2026 | 3,833 | $421.32K | Aug 7, 2026 | Exercise of Stock Options |
| Marino Garcia Director, Officer | Aug 7, 2026 | 40,000 | $4.40M | Aug 7, 2026 | Exercise of Stock Options |
| Ryan Savitz Officer | Jul 9, 2026 | 31,249 | $3.06M | Jul 9, 2026 | Exercise of Stock Options |
| Adam M. Veness Officer | Jun 17, 2026 | 30,000 | $2.37M | Jun 17, 2026 | Exercise of Stock Options |
| Simrat Randhawa Officer | Jun 1, 2026 | 26,530 | $2.47M | Jun 1, 2026 | Exercise of Stock Options |
| Ryan Savitz Officer | Apr 9, 2026 | 8,224 | $719.44K | Apr 9, 2026 | Exercise of Stock Options |
| Ryan Savitz Officer | Mar 31, 2026 | 114,367 | $9.09M | Mar 31, 2026 | Exercise of Stock Options |
| Paula Soteropoulos Director | Mar 31, 2026 | 1,198 | $95.18K | Mar 31, 2026 | Exercise of Stock Options |
See a number that looks wrong?